Paraplegia

Summary

Paraplegia (MONDO:0003757) is a disease and 55 clinical trials. Top therapeutic interventions include ursolic acid. A subtype of palsy — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 55

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	paraplegia
Mondo ID	MONDO:0003757
EFO	EFO:0009679
MeSH	D010264
DOID	DOID:607
ICD-10-CM	G82.2
ICD-11	1212533558
NCIT	C50687
SNOMED CT	60389000
UMLS	C0030486
MedGen	45323
Is cancer (heuristic)	no

Also known as: severe or complete loss of motor function in the lower extremities and lower portions of the trunk

Disease family

This is a subtype of palsy. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › palsy › paraplegia

Related subtypes (9): hemiplegia, quadriplegia, facial paralysis, ophthalmoplegia, cerebral palsy, progressive bulbar palsy, klumpke’s paralysis, respiratory paralysis, Erb palsy

Subtypes (2): Brown-Sequard syndrome, hereditary spastic paraplegia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

No approved or late-stage (phase ≥3) drug is indicated for this disease; the following are in earlier-phase trials only.

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Atorvastatin, Chenodiol, Resveratrol.

Clinical trials & evidence

Clinical trials

Clinical trials: 55.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	46
PHASE3	3
PHASE2	2
PHASE1	2
PHASE2/PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00059553	PHASE2/PHASE3	UNKNOWN	Retraining Walking After Spinal Cord Injury
NCT01569360	PHASE3	WITHDRAWN	Study of the Impact of the Use of a Corset on the Respiratory Function of Patients With Spinal Cord Injury
NCT06071949	PHASE3	UNKNOWN	Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis
NCT06072001	PHASE3	UNKNOWN	Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis
NCT00429013	PHASE2	TERMINATED	Pressure Ulcer Formation Prevention in Paraplegics Using Computer and Sensory Substitution Via the Tongue.
NCT01498991	PHASE1/PHASE2	TERMINATED	Spinal Cord Injury Leg Rehabilitation
NCT05776862	PHASE2	COMPLETED	Study Testing Benefits of Ursolic Acid (UA) as a Countermeasure To Myopenia and Insulin Resistance in Chronic Spinal Cord Injury (SCI)
NCT01739023	PHASE1	COMPLETED	Safety of Autologous Human Schwann Cells (ahSC) in Subjects With Subacute SCI
NCT02354625	PHASE1	COMPLETED	The Safety of ahSC in Chronic SCI With Rehabilitation
NCT00623389	Not specified	RECRUITING	Evaluation of an Advanced Lower Extremity Neuroprostheses
NCT01474148	Not specified	RECRUITING	A Neuroprosthesis for Seated Posture and Balance
NCT02600910	Not specified	ACTIVE_NOT_RECRUITING	Natural History of Shoulder Pathology in Manual Wheelchair Users
NCT03225625	Not specified	ENROLLING_BY_INVITATION	Stem Cell Spinal Cord Injury Exoskeleton and Virtual Reality Treatment Study
NCT05483764	Not specified	ACTIVE_NOT_RECRUITING	Ultrasonographic Measurements of the Achilles Tendon and Talar Condylar Cartilage Thickness in Paraplegia Patients.
NCT06243952	Not specified	RECRUITING	Brain Controlled Spinal Cord Stimulation In Participants With Spinal Cord Injury For Lower Limb Rehabilitation
NCT06295146	Not specified	RECRUITING	Virtual Peer Coaching in Manual Wheelchair Skills
NCT07583576	Not specified	NOT_YET_RECRUITING	Effects of Functional Electrical Stimulation on Spasticity, Quadriceps Muscle Strength and Functional Mobility in Individuals With Paraplegia
NCT00221767	Not specified	COMPLETED	Medico-economical Impact of the Brindley Neurosurgical Technique in France
NCT00270855	Not specified	COMPLETED	Exercise to Reduce Obesity in Spinal Cord Injury
NCT00385918	Not specified	COMPLETED	Robotically Assisted Treadmill Training in Spinal Cord Injury (SCI)
NCT00627107	Not specified	COMPLETED	A Study Testing Safety and Tolerance of the ReWalk Exoskeleton Suit
NCT00785278	Not specified	UNKNOWN	Adjusting Wheelchair Set-Up to Minimize Shoulder Joint Forces During Propulsion
NCT00838838	Not specified	COMPLETED	Efficacy of Nebido on Bone Mineral Density (BMD) in Hypogonadal Paraplegic Patients With Confirmed Osteoporosis
NCT00957762	Not specified	UNKNOWN	Body Composition Assessment in Spinal Cord Injury
NCT01251549	Not specified	COMPLETED	Safety and Performance Evaluation of ReWalk Reciprocating Gait Orthosis (RGO)
NCT01454570	Not specified	COMPLETED	The ReWalk Exoskeletal Walking System for Persons With Paraplegia
NCT01740128	Not specified	COMPLETED	Multimodal Exercises to Improve Leg Function After Spinal Cord Injury
NCT01923662	Not specified	COMPLETED	A Neuroprosthesis for Prolonged Standing After SCI Using Multi-Contact Peripheral Nerve Electrodes
NCT02042508	Not specified	COMPLETED	Evaluation of a Hybrid Prototype Strategy (Electrostimulation of Lower Limb Muscles Associated With Voluntary Strengthening of the Upper Limbs) in Reconditioning to Effort in Patients With Chronic Paraplegia.
NCT02314221	Not specified	COMPLETED	Exoskeletal-assisted Walking to Improve Mobility, Bowel Function and Cardio-Metabolic Profiles in Persons With SCI
NCT02412046	Not specified	TERMINATED	Quantification of the Pressure Threshold Related to Tissue Injury in Bedriden Paraplegics
NCT02602639	Not specified	UNKNOWN	Functional Electrical Stimulation With Rowing as Exercise After Spinal Cord Injury
NCT03114345	Not specified	TERMINATED	Correlation Between Pressure Differences and Micro-vascularization Changes in Bedridden Paraplegic Patient
NCT03386799	Not specified	COMPLETED	Evaluation of a Power Assistance Device for Wheelchair-DUO
NCT03495986	Not specified	COMPLETED	Spinal Cord Injury Exercise and Nutrition Conceptual Engagement
NCT03992690	Not specified	UNKNOWN	Training With Brain-machine Interfaces, Visuo-tactile Feedback and Assisted Locomotion for Patients With Chronic Complete Paraplegia
NCT04011137	Not specified	COMPLETED	High-intensity Interval Training and Mixed Meal Responses in Persons With Spinal Cord Injury
NCT04055610	Not specified	UNKNOWN	Gait Training for Individuals With Paraplegia Using the H-MEX Exoskeleton
NCT04064385	Not specified	UNKNOWN	Functional Electrical Stimulation Cycling in SCI
NCT04110561	Not specified	COMPLETED	Evaluation of Safety and Performance of the Atalante System With Patients With Lower Limb Paralysis

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
URSOLIC ACID	2	1